Fabry Disease News and Research

RSS
Fabry disease (also known as Fabry's disease, Anderson-Fabry disease, angiokeratoma corporis diffusum and alpha-galactosidase A deficiency) is a rare X-linked recessive (inherited) lysosomal storage disease, which can cause a wide range of systemic symptoms.
iBio receives U.S. patent entitled 'System for Expression of Genes in Plants'

iBio receives U.S. patent entitled 'System for Expression of Genes in Plants'

PerkinElmer Genetics launches new Lysosomal Storage Disorder panel

PerkinElmer Genetics launches new Lysosomal Storage Disorder panel

FDA accepts Protalix taliglucerase alfa NDA resubmission for review

FDA accepts Protalix taliglucerase alfa NDA resubmission for review

Spanish patients with Fabry disease show classic observable traits different from rest of Europe

Spanish patients with Fabry disease show classic observable traits different from rest of Europe

EMA approves Shire's new REPLAGAL manufacturing facility in Lexington

EMA approves Shire's new REPLAGAL manufacturing facility in Lexington

Shire's Replagal and VPRIV data on Gaucher and Fabry patients presented at ACMG meeting

Shire's Replagal and VPRIV data on Gaucher and Fabry patients presented at ACMG meeting

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Protalix receives FDA CRL for taliglucerase alfa NDA for Gaucher disease

Protalix receives FDA CRL for taliglucerase alfa NDA for Gaucher disease

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

2010 Mid-Atlantic Bio a great kick-off for hosting 2011 BIO International Convention

2010 Mid-Atlantic Bio a great kick-off for hosting 2011 BIO International Convention

GSK and Amicus announce Amigal development and commercialization agreement

GSK and Amicus announce Amigal development and commercialization agreement

Neuraltus achieves last patient out for NP001, NP002 studies

Neuraltus achieves last patient out for NP001, NP002 studies

Genzyme responds to Sanofi-Aventis' unsolicited acquisition proposal

Genzyme responds to Sanofi-Aventis' unsolicited acquisition proposal

Genzyme signs consent decree of permanent injunction, agrees to disgorgement

Genzyme signs consent decree of permanent injunction, agrees to disgorgement

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

Determining personal risk for genetic disorders essential

Determining personal risk for genetic disorders essential

Genetic Disorder Tracker introduced by Guidepoint Global

Genetic Disorder Tracker introduced by Guidepoint Global

Shire receives FDA Fast Track designation for REPLAGAL

Shire receives FDA Fast Track designation for REPLAGAL